Patents by Inventor Glenn T. Miller
Glenn T. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080221068Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.Type: ApplicationFiled: October 15, 2007Publication date: September 11, 2008Applicant: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller
-
Patent number: 7282484Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.Type: GrantFiled: June 28, 2006Date of Patent: October 16, 2007Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller
-
Patent number: 7259138Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.Type: GrantFiled: May 17, 2005Date of Patent: August 21, 2007Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller
-
Patent number: 7067489Abstract: Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. The products include kits comprising the agent of Formula I.Type: GrantFiled: June 28, 2004Date of Patent: June 27, 2006Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Barry Jones, Glenn T. Miller, Sharlene Adams
-
Patent number: 6770628Abstract: Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.Type: GrantFiled: June 11, 2001Date of Patent: August 3, 2004Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Barry Jones, Glenn T. Miller, Sharlene Adams
-
Publication number: 20040077601Abstract: A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease. Compositions containing Ile-boroPro compounds are also provided. The invention embraces the use of these compounds alone or in combination with other therapeutic agents.Type: ApplicationFiled: July 9, 2003Publication date: April 22, 2004Applicant: Point Therapeutics, Inc.Inventors: Sharlene Adams, Glenn T. Miller, Michael I. Jesson, Barry Jones
-
Publication number: 20020013279Abstract: Methods and products for stimulating hematopoietic, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and, mature blood cells are provided. The methods and products can be used both in vivo and in vitro.Type: ApplicationFiled: June 11, 2001Publication date: January 31, 2002Inventors: Barbara P. Wallner, Barry Jones, Glenn T. Miller, Sharlene Adams
-
Patent number: 6300314Abstract: Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.Type: GrantFiled: May 3, 1999Date of Patent: October 9, 2001Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Barry Jones, Glenn T. Miller, Sharlene Adams
-
Patent number: 5928643Abstract: Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.Type: GrantFiled: June 2, 1995Date of Patent: July 27, 1999Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller, Margaret D. Rosa
-
Patent number: 5914111Abstract: Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.Type: GrantFiled: June 2, 1995Date of Patent: June 22, 1999Assignee: Biogen Inc.Inventors: Barbara P. Wallner, Glenn T. Miller, Margaret D. Rosa
-
Patent number: 5728677Abstract: Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.Type: GrantFiled: June 2, 1995Date of Patent: March 17, 1998Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller, Margaret D. Rosa
-
Patent number: 5547853Abstract: Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.Type: GrantFiled: October 21, 1992Date of Patent: August 20, 1996Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller, Margaret D. Rosa